David A. Van Echo

4.2k citations
87 papers · 3.7k · 1 hit paper · h-index 29

Impact in

  • Oncology top 2%
    • Cancer Treatment and Pharmacology
    • Metal complexes synthesis and properties
    • Lung Cancer Research Studies
    • Nanoparticle-Based Drug Delivery

Papers in

    • Lung Cancer Research Studies 9
    • Cancer Treatment and Pharmacology 8
    • Bioactive Compounds and Antitumor Agents 9

David A. Van Echo

86 papers receiving 3.4k citations

David A. Van Echo's Hit Papers

Hypersensitivity reactions from taxol. 1990 · 1k citations
1k0+12+24Years since publication2505007501k

Peers

David A. Van Echo
Comparison fields: 5 of 94
  • Oncology 1.2k
  • Biomaterials 467
  • Otorhinolaryngology 158
  • Pharmacology 235
  • Pharmaceutical Science 140
Replace Sewa S. Legha with:
Sewa S. Legha United States
Marcel Rozencweig United States
Bryan Leyland-Jones United States
Renzo M. Canetta United States
Alain C. Mita United States
J Cassidy United Kingdom
Barry R. Goldspiel United States
Robert J. Morgan United States
Francois Marc Lokiec France
Dominic T. Moore United States
David A. Van Echo relative to Sewa S. Legha United States Sewa S. Legha's profile →
Citations per field
00.5×2×2.9×
Sewa S. Legha · 1×
Citations per year

Countries citing papers authored by David A. Van Echo

Since Specialization
Citations

This map shows the geographic impact of David A. Van Echo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Van Echo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Van Echo more than expected).

Fields of papers citing papers by David A. Van Echo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Van Echo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Van Echo. The network helps show where David A. Van Echo may publish in the future.

Co-authors

The 25 scholars most cited alongside David A. Van Echo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David A. Van Echo Line = papers co-authored together David A. Van Echo links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 87 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Hypersensitivity reactions from taxol.
Hit paper breakdown →
19901022
2
Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.
1984279
3 1990176
4
Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum.
1985170
5
Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.
1998135
6
Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations.
1982114
7
Value of prophylactic cranial irradiation given at complete remission in small cell lung carcinoma.
198396
8 200089
9
Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
198769
10 200169
11
Phase I clinical and pharmacologic trial of carboplatin daily for 5 days.
198467
12 199766
13 200359
14
Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
198653
15 198351
16
The pharmacology of carboplatin.
198950
17 198146
18 199346
19 200145
20 198441

About David A. Van Echo

David A. Van Echo is a scholar working on Oncology, Toxicology, Otorhinolaryngology, Hematology and Pulmonary and Respiratory Medicine, having authored 87 papers that have together received 3.7k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (20 papers), Acute Myeloid Leukemia Research (11 papers), Bioactive Compounds and Antitumor Agents (9 papers), Lung Cancer Research Studies (9 papers), Lung Cancer Diagnosis and Treatment (8 papers), Head and Neck Cancer Studies (8 papers), Cancer Treatment and Pharmacology (8 papers) and Retinoids in leukemia and cellular processes (8 papers). The work is most often cited by research in Oncology (1.2k citations), Biomaterials (467 citations), Otorhinolaryngology (158 citations), Pharmacology (235 citations) and Pharmaceutical Science (140 citations). David A. Van Echo has collaborated with scholars based in United States, Israel and Ukraine. Frequent co-authors include Joseph Aisner, Peter H. Wiernik, Margaret Y. Whitacre, Merrill J. Egorin, Ross C. Donehower, Daniel D. Von Hoff, T Ohnuma, R B Weiss, D L Trump and Richard J. Gralla. Their work appears in journals such as Cancer Chemotherapy and Pharmacology, Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics, Cancer and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact